Staff Profile
Dr Asima Mukhopadhyay
Associate Clinical Researcher
Publications
- Kotsopoulos IC, Begbie JA, Mukhopadhyay A, Lunec J, Curtin NJ, Kucukmetin A. IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
- Abdulrahman GO, Davison E, Matheson E, Drew Y, Curtin N, Mukhopadhyay A. Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
- Bizzarri N, Bradbury M, O'Donnell RL, Rundle S, Ghirardi V, Natsis S, Kotsopoulos IC, Ang C, Kucukmetin A, Fisher AD, Godfrey KA, Ratnavelu N, Naik R, Bhaumik J, Ghosh A, Chakraboti B, Helm CW, Mukhopadhyay A. Metastatic involvement of the lesser sac in advanced epithelial ovarian cancer. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
- Mukhopadhyay A, Shinde A, Naik R. Ovarian cysts and cancer in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology 2016, 33, 58-72.
- Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors. International Journal of Gynecological Cancer 2016, 26(4), 763-769.
- Matheson E, Salehan M, Mukhopadhyay A, Curtin NJ, Drew Y. Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer. In: 16th Biennial Meeting of the International Gynecologic Cancer Society. 2016, Lisbon, Portugal: Lippincott Williams & Wilkins, Ltd.
- Mukhopadhyay A, Dixon M, Mulligan E, Schuhwerk H, Murray J, Quinn J, Van Nest L, Van Criekinge W, Curtin N, Edmondson R. Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer. In: The 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014). 2014, Melbourne, Australia: Lippincott Williams & Wilkins.
- Edmondson RJ, Mukhopadhyay A, Van Neste L, Van Criekinge W, Curtin N. Molecular characterization of matched ovarian ascites and tumors suggests multiple mechanisms for a homologous recombination defective phenotype. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
- O'Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufmann A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ. The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis. PLoS ONE 2014, 9(3), e90604.
- ODonnell R, Woodhouse L, McCormick A, Mukhopadhyay A, Dixon M, Kaufmann A, Curtin NJ, Edmondson RJ. Functional Intra-Tumour Heterogeneity in Ovarian Cancer: What is a Representative Tumour Sample?. In: 18th International Meeting of the European Society of Gynaecological Oncology (ESGO). 2013, Liverpool, UK: Lippincott Williams & Wilkins.